Lv2
134 积分 2025-05-14 加入
Efficacy and safety of immune checkpoint inhibitors in EGFR-mutant NSCLC patients with EGFR-TKI resistance: an updated systematic review and meta-analysis
1天前
待确认
Immunotherapy in EGFR-mutant NSCLC after TKI resistance: role of mutation subtypes and progression patterns
1天前
已完结
Addressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategies
1天前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
1天前
已完结
皖公网安备34019202002308
